Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

UX053

Gene therapy · developed by Ultragenyx Pharmaceutical

Phase 1/2 Most advanced trial (none active)
RARE Developer
1 Registered trials

What is UX053?

UX053 is a drug studied in glycogen storage disease type III.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Therapy area
Metabolic
Developer
Ultragenyx Pharmaceutical Inc (RARE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04990388 Phase 1/2 Glycogen Storage Disease Type III Terminated RARE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glycogen Storage Disease Type III

More from Ultragenyx Pharmaceutical

Follow RARE, the company behind UX053

See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RARE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.